Protein kinase C is a promising host target for anticoronaviral therapy in vitro and in vivo
Virology · 2027-02 · 626 · 111141
DOI: 10.1016/j.virol.2026.111141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virology, 2027-02. Verfasst von Changbai Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Diseases Control (Sun Yat-sen University), Ministry of Education, Guangzhou, 510080, China; Department of Immunology and M…. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Host-directed antiviral strategies are urgently needed to counteract emerging SARS-CoV-2 variants. Protein kinase C (PKC) family members are involved in the replication of multiple viruses, but their role in coronavirus infections remains unclear. Building on our previous finding that pan-PKC inhibitors suppress SARS-CoV-2 replication in cultured cells, we herein investigated the underlying mechanism and evaluated the in vivo antiviral efficacy of PKC inhibitors in a mouse hepatitis virus (MHV)-infected mouse model. Go 6983, bisindolylmaleimide I, and sotrastaurin significantly reduced PKCα phosphorylation in Huh7 cells, whereas enzastaurin exhibited only a weak inhibitory effect. Importantly, siRNA-mediated knockdown of PKCα, δ, ε, and ζ substantially impaired SARS-CoV-2 replicon and viral trVLP replication, indicating that multiple PKC isoforms contribute to coronavirus replication. These inhibitors exhibited low cytotoxicity in murine 17Cl-1 cells and reduced MHV-induced cytopathic effects. In BALB/c mice, daily intraperitoneal administration of Go 6983 or bisindolylmaleimide I caused no body weight loss or pulmonary histopathological changes. Prophylactic treatment significantly suppressed lung viral RNA copies by 1-3 orders of magnitude, and alleviated virus-induced inflammation in both the lung and liver. Collectively, our results suggest that multiple PKC isoforms are potential host factors involved in coronavirus replication and PKC inhibitors exert potent antiviral and anti-inflammatory activity in vivo. These findings support the notion that PKC represents a promising host-directed antiviral target against coronaviruses, including SARS-CoV-2.
Autor:innen und Institutionen
- Key Laboratory of Tropical Diseases Control (Sun Yat-sen University), Ministry of Education, Guangzhou, 510080, China; Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Gua…
- Pathogenic Biology Laboratory, Experimental Center for Basic Medical Teaching, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
- Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. Electronic address: ychao@mail.sysu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, C., Ju, L., Luo, Y., Chen, J., Zhu, X., Sun, Z., Zhang, P., Yang, C., & Liu, C. (2027). Protein kinase C is a promising host target for anticoronaviral therapy in vitro and in vivo. Virology, 626, 111141. https://doi.org/10.1016/j.virol.2026.111141
Vancouver
Huang C, Ju L, Luo Y, Chen J, Zhu X, Sun Z, et al. Protein kinase C is a promising host target for anticoronaviral therapy in vitro and in vivo. Virology. 2027;626:111141. doi:10.1016/j.virol.2026.111141
BibTeX
@article{Huang2027,
author = {Huang, Changbai and Ju, Liliang and Luo, Yingrui and Chen, Jianhuang and Zhu, Xuanfeng and Sun, Zhixian and Zhang, Ping and Yang, Chao and Liu, Chao},
title = {Protein kinase C is a promising host target for anticoronaviral therapy in vitro and in vivo},
journal = {Virology},
year = {2027},
volume = {626},
pages = {111141},
doi = {10.1016/j.virol.2026.111141}
}
EUVIMED